Uptake and population-level impact of expedited partner therapy (EPT) on Chlamydia trachomatis and Neisseria gonorrhoeae: the Washington State community-level randomized trial of EPT
- PMID: 25590331
- PMCID: PMC4295847
- DOI: 10.1371/journal.pmed.1001777
Uptake and population-level impact of expedited partner therapy (EPT) on Chlamydia trachomatis and Neisseria gonorrhoeae: the Washington State community-level randomized trial of EPT
Abstract
Background: Expedited partner therapy (EPT), the practice of treating the sex partners of persons with sexually transmitted infections without their medical evaluation, increases partner treatment and decreases gonorrhea and chlamydia reinfection rates. We conducted a stepped-wedge, community-level randomized trial to determine whether a public health intervention promoting EPT could increase its use and decrease chlamydia test positivity and gonorrhea incidence in women.
Methods and findings: The trial randomly assigned local health jurisdictions (LHJs) in Washington State, US, into four study waves. Waves instituted the intervention in randomly assigned order at intervals of 6-8 mo. Of the state's 25 LHJs, 24 were eligible and 23 participated. Heterosexual individuals with gonorrhea or chlamydial infection were eligible for the intervention. The study made free patient-delivered partner therapy (PDPT) available to clinicians, and provided public health partner services based on clinician referral. The main study outcomes were chlamydia test positivity among women ages 14-25 y in 219 sentinel clinics, and incidence of reported gonorrhea in women, both measured at the community level. Receipt of PDPT from clinicians was evaluated among randomly selected patients. 23 and 22 LHJs provided data on gonorrhea and chlamydia outcomes, respectively. The intervention increased the percentage of persons receiving PDPT from clinicians (from 18% to 34%, p < 0.001) and the percentage receiving partner services (from 25% to 45%, p < 0.001). Chlamydia test positivity and gonorrhea incidence in women decreased over the study period, from 8.2% to 6.5% and from 59.6 to 26.4 per 100,000, respectively. After adjusting for temporal trends, the intervention was associated with an approximately 10% reduction in both chlamydia positivity and gonorrhea incidence, though the confidence bounds on these outcomes both crossed one (chlamydia positivity prevalence ratio = 0.89, 95% CI 0.77-1.04, p = 0.15; gonorrhea incidence rate ratio = 0.91, 95% CI .71-1.16, p = 0.45). Study findings were potentially limited by inadequate statistical power, by the institution of some aspects of the study intervention outside of the research randomization sequence, and by the fact that LHJs did not constitute truly isolated sexual networks.
Conclusions: A public health intervention promoting the use of free PDPT substantially increased its use and may have resulted in decreased chlamydial and gonococcal infections at the population level.
Trial registration: ClinicalTrials.gov NCT01665690.
Conflict of interest statement
Pfizer pharmaceuticals provided free azithromycin used in the study. MRG has received research support from Melinta pharmacueticals and Cempra pharmaceuticals for his participation as an investigator in trials of new drug treatments for gonorrhea. MRG has received a consulting fee from Melinta pharmaceuticals.
Figures
References
-
- Centers for Disease Control and Prevention (2013) Sexually transmitted disease surveillance 2012. Atlanta: Centers for Disease Control and Prevention;
-
- Golden MR, Hogben M, Potterat JJ, Handsfield HH (2004) HIV partner notification in the United States: a national survey of program coverage and outcomes. Sex Transm Dis 31: 709–712. - PubMed
-
- Schillinger JA, Kissinger P, Calvet H, Whittington WL, Ransom RL, et al. (2003) Patient-delivered partner treatment with azithromycin to prevent repeated Chlamydia trachomatis infection among women: a randomized, controlled trial. Sex Transm Dis 30: 49–56. - PubMed
-
- Golden MR, Whittington WL, Handsfield HH, Hughes JP, Stamm WE, et al. (2005) Effect of expedited treatment of sex partners on recurrent or persistent gonorrhea or chlamydial infection. N Engl J Med 352: 676–685. - PubMed
-
- Kissinger P, Mohammed H, Richardson-Alston G, Leichliter JS, Taylor SN, et al. (2005) Patient-delivered partner treatment for male urethritis: a randomized, controlled trial. Clin Infect Dis 41: 623–629. - PubMed
Publication types
MeSH terms
Substances
Associated data
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
